Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Completed · Phase 1
Conditions studied: Carcinoid Tumor, Acromegaly
In brief
This study will assess the pharmacokinetic profile and the safety/tolerability profile of single and monthly doses of pasireotide LAR intramuscular (i.m.) injection in patients with acromegaly and patients with carcinoid disease
Key facts
- Study ID
- NCT00446082
- Run by
- Novartis Pharmaceuticals
- People needed
- 85
- Starts
- 2006-06-01
- Expected to finish
- 2013-11-01
- Last updated by the study team
- 2020-12-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cedars Sinai Medical Center SC - 4 — Los Angeles, California, United States
- Stanford University Medical Center Stanford Cancer Center (3) — Stanford, California, United States
- H. Lee Moffitt Cancer Center & Research Institute Dept.of H.LeeMoffittCC&RI(1) — Tampa, Florida, United States
- University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology — Houston, Texas, United States
- Novartis Investigative Site — Brussels, Belgium
- Novartis Investigative Site — Leuven, Belgium
- Novartis Investigative Site — Liège, Belgium
- Novartis Investigative Site — London, Ontario, Canada
- Novartis Investigative Site — Toronto, Ontario, Canada
- Novartis Investigative Site — Montreal, Quebec, Canada
- Novartis Investigative Site — Berlin, Germany
- Novartis Investigative Site — Berlin, Germany
- Novartis Investigative Site — Essen, Germany
- Novartis Investigative Site — Leipzig, Germany
- Novartis Investigative Site — München, Germany
- Novartis Investigative Site — Rotterdam, Netherlands
- Novartis Investigative Site — Oslo, Norway
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.